Safety of mogamulizumab in mycosis fungoides and sezary syndrome: final results from the Phase 3 Mavoric Study
Authors
Kim, Y.Bagot, M.
Zinzani, P. L.
Morris, S.
Ortiz-Romero, P.
Magnolo, N.
Scarisbrick, J.
Dalle, S.
Quaglino, P.
Dreno, B.
Beylot-Barry, M.
Caballero, D.
Cowan, Richard A
Dummer, R.
Iversen, L.
Vermeer, M.
Nicolay, J.
Affiliation
Stanford Cancer Center, Stanford, CaIssue Date
2022